Unjoni Ewropea - Svediż - EMA (European Medicines Agency)

ucb pharma s.a.   - fenfluramine hydrochloride - epilepsies, myoclonic - antiepileptika, - treatment of seizures associated with dravet syndrome as an add-on therapy to other antiepileptic medicines for patients 2 years of age and older. fintepla is indicated for the treatment of seizures associated with dravet syndrome and lennox-gastaut syndrome as an add-on therapy to other anti-epileptic medicines for patients 2 years of age and older.

Unjoni Ewropea - Svediż - EMA (European Medicines Agency)

roche registration gmbh  - pralsetinib - carcinom, non-small cell lung - antineoplastiska medel - gavreto is indicated as monotherapy for the treatment of adult patients with rearranged during transfection (ret) fusion-positive advanced non-small cell lung cancer (nsclc) not previously treated with a ret inhibitor.

Unjoni Ewropea - Svediż - EMA (European Medicines Agency)

bial portela & companhia s.a. - opicapone - parkinsons sjukdom - anti-parkinson-läkemedel - ontilyv is indicated as adjunctive therapy to preparations of levodopa/ dopa decarboxylase inhibitors (ddci) in adult patients with parkinson’s disease and end-of-dose motor fluctuations who cannot be stabilised on those combinations.

Unjoni Ewropea - Svediż - EMA (European Medicines Agency)

novartis europharm limited  - capmatinib dihydrochloride monohydrate - carcinom, non-small cell lung - antineoplastiska medel - tabrecta as monotherapy is indicated for the treatment of adult patients with advanced non small cell lung cancer (nsclc) harbouring alterations leading to mesenchymal epithelial transition factor gene exon 14 (metex14) skipping, who require systemic therapy following prior treatment with immunotherapy and/or platinum based chemotherapy.

Unjoni Ewropea - Svediż - EMA (European Medicines Agency)

stemline therapeutics b.v. - elacestrant - bröst-neoplasmer - endokrin terapi - orserdu monotherapy is indicated for the treatment of postmenopausal women, and men, with estrogen receptor (er) positive, her2-negative, locally advanced or metastatic breast cancer with an activating esr1 mutation who have disease progression following at least one line of endocrine therapy including a cdk 4/6 inhibitor.

Unjoni Ewropea - Svediż - EMA (European Medicines Agency)

daiichi sankyo europe gmbh - quizartinib dihydrochloride - leukemi, myeloid - antineoplastic agents, protein kinase inhibitors - vanflyta is indicated in combination with standard cytarabine and anthracycline induction and standard cytarabine consolidation chemotherapy, followed by vanflyta single-agent maintenance therapy for adult patients with newly diagnosed acute myeloid leukaemia (aml) that is flt3-itd positive.

Żvezja - Svediż - Läkemedelsverket (Medical Products Agency)

fresenius kabi ab - alanin; arginin; asparaginsyra; cysteinhydrokloridmonohydrat; fenylalanin; glutaminsyra; glycin; histidin; isoleucin; kalciumglukonat (monohydrat); kaliumklorid; leucin; lysinhydroklorid; magnesiumsulfatheptahydrat; metionin; natriumacetattrihydrat; prolin; serin; treonin; tryptofan; tyrosin; valin - infusionsvätska, lösning - leucin 5,9 mg aktiv substans; metionin 4,2 mg aktiv substans; fenylalanin 5,9 mg aktiv substans; histidin 5,1 mg aktiv substans; treonin 4,2 mg aktiv substans; tryptofan 1,4 mg aktiv substans; isoleucin 4,2 mg aktiv substans; arginin 8,4 mg aktiv substans; natriumacetattrihydrat 13,6 mg aktiv substans; prolin 5,1 mg aktiv substans; kalciumglukonat (monohydrat) 2,24 mg aktiv substans; lysinhydroklorid 8,38 mg aktiv substans; asparaginsyra 2,5 mg aktiv substans; glutaminsyra 4,2 mg aktiv substans; kaliumklorid 3,73 mg aktiv substans; magnesiumsulfatheptahydrat 1,97 mg aktiv substans; tyrosin 170 mikrog aktiv substans; serin 3,4 mg aktiv substans; alanin 12 mg aktiv substans; glycin 5,9 mg aktiv substans; cysteinhydrokloridmonohydrat 526,14 mikrog aktiv substans; valin 5,5 mg aktiv substans - aminosyror

Żvezja - Svediż - Läkemedelsverket (Medical Products Agency)

fresenius kabi ab - alanin; arginin; asparaginsyra; cystein; fenylalanin; glutaminsyra; glycin; histidin; isoleucin; leucin; lysinacetat; metionin; prolin; serin; treonin; tryptofan; tyrosin; valin - infusionsvätska, lösning - cystein 560 mikrog aktiv substans; glycin 7,9 mg aktiv substans; alanin 16 mg aktiv substans; serin 4,5 mg aktiv substans; tyrosin 230 mikrog aktiv substans; leucin 7,9 mg aktiv substans; metionin 5,6 mg aktiv substans; fenylalanin 7,9 mg aktiv substans; histidin 6,8 mg aktiv substans; valin 7,3 mg aktiv substans; treonin 5,6 mg aktiv substans; tryptofan 1,9 mg aktiv substans; isoleucin 5,6 mg aktiv substans; arginin 11,3 mg aktiv substans; prolin 6,8 mg aktiv substans; asparaginsyra 3,4 mg aktiv substans; glutaminsyra 5,6 mg aktiv substans; lysinacetat 12,7 mg aktiv substans - aminosyror

Unjoni Ewropea - Svediż - EMA (European Medicines Agency)

recordati rare diseases - cargluminsyra - amino acid metabolism, inborn errors; propionic acidemia - andra matsmältningsorgan och ämnesomsättning produkter, - carbaglu är indicerat för behandling av:hyperammonaemia på grund av n-acetylglutamate-syntas främsta brist. hyperammonaemia på grund av isovaleric acidaemia;hyperammonaemia på grund av methymalonic acidaemia;hyperammonaemia på grund av propionsyra acidaemia.

Żvezja - Svediż - Läkemedelsverket (Medical Products Agency)

fresenius kabi ab - kaliumjodid; kopparkloriddihydrat; mangankloridtetrahydrat; natriumselenit, vattenfri; zinkklorid - koncentrat till infusionsvätska, lösning - zinkklorid 1042 mikrog aktiv substans; natriumselenit, vattenfri 15,33 mikrog aktiv substans; kaliumjodid 2,567 mikrog aktiv substans; kopparkloriddihydrat 107,4 mikrog aktiv substans; mangankloridtetrahydrat 3,6 mikrog aktiv substans